Ubs Group Ag Axsome Therapeutics, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 39,704 shares of AXSM stock, worth $3.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,704

Previous 61,320 35.25%

Holding current value

$3.56 Million

Previous $4.89 Million 34.68%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$65.72 - $80.5 $1.42 Million - $1.74 Million	-21,616 Reduced 35.25%	39,704 $3.2 Million
Q1 2024 May 13, 2024	BUY	$69.39 - $97.64 $1.47 Million - $2.07 Million	21,195 Added 52.82%	61,320 $4.89 Million
Q4 2023 Feb 09, 2024	BUY	$57.42 - $83.61 $421,520 - $613,781	7,341 Added 22.39%	40,125 $3.19 Million
Q3 2023 Nov 09, 2023	BUY	$69.25 - $82.21 $1.26 Million - $1.5 Million	18,205 Added 124.87%	32,784 $2.29 Million
Q2 2023 Aug 11, 2023	SELL	$58.41 - $90.35 $98,829 - $152,872	-1,692 Reduced 10.4%	14,579 $1.05 Million
Q1 2023 May 12, 2023	BUY	$58.39 - $75.0 $187,665 - $241,050	3,214 Added 24.62%	16,271 $1 Million
Q4 2022 Feb 08, 2023	SELL	$39.94 - $79.72 $209,445 - $418,051	-5,244 Reduced 28.65%	13,057 $1.01 Million
Q3 2022 Nov 10, 2022	BUY	$36.06 - $69.85 $141,138 - $273,392	3,914 Added 27.21%	18,301 $817,000
Q2 2022 Aug 10, 2022	SELL	$21.74 - $46.75 $43,566 - $93,687	-2,004 Reduced 12.23%	14,387 $551,000
Q1 2022 May 16, 2022	BUY	$23.7 - $41.39 $316,560 - $552,846	13,357 Added 440.24%	16,391 $678,000
Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $193,778 - $273,688	-6,312 Reduced 67.54%	3,034 $114,000
Q3 2021 Nov 15, 2021	SELL	$19.91 - $68.26 $36,554 - $125,325	-1,836 Reduced 16.42%	9,346 $308,000
Q2 2021 Aug 13, 2021	BUY	$50.63 - $73.5 $87,994 - $127,743	1,738 Added 18.4%	11,182 $754,000
Q1 2021 May 12, 2021	BUY	$55.91 - $81.44 $29,632 - $43,163	530 Added 5.95%	9,444 $535,000
Q4 2020 Feb 11, 2021	SELL	$66.31 - $86.52 $300,981 - $392,714	-4,539 Reduced 33.74%	8,914 $726,000
Q3 2020 Nov 12, 2020	SELL	$68.34 - $85.84 $253,678 - $318,638	-3,712 Reduced 21.63%	13,453 $959,000
Q2 2020 Jul 31, 2020	SELL	$49.87 - $98.69 $189,107 - $374,232	-3,792 Reduced 18.09%	17,165 $1.41 Million
Q1 2020 May 01, 2020	SELL	$41.2 - $101.31 $966,675 - $2.38 Million	-23,463 Reduced 52.82%	20,957 $1.23 Million
Q4 2019 Feb 14, 2020	SELL	$16.71 - $106.24 $22,090 - $140,449	-1,322 Reduced 2.89%	44,420 $4.59 Million
Q3 2019 Nov 14, 2019	BUY	$20.24 - $29.16 $857,710 - $1.24 Million	42,377 Added 1259.35%	45,742 $926,000
Q2 2019 Aug 14, 2019	BUY	$13.46 - $25.75 $20,593 - $39,397	1,530 Added 83.38%	3,365 $86,000
Q1 2019 May 14, 2019	BUY	$2.63 - $16.34 $4,826 - $29,983	1,835 New	1,835 $26,000
Q3 2018 Nov 14, 2018	SELL	$2.3 - $3.55 $641 - $990	-279 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.15 - $3.6 $599 - $1,004	279 New	279 $1,000
Q4 2017 Feb 14, 2018	SELL	$4.45 - $6.2 $1,068 - $1,488	-240 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$4.65 - $6.1 $5,310 - $6,966	-1,142 Reduced 82.63%	240 $1,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,113 Added 413.75%	1,382 $8,000
Q1 2017 Nov 14, 2017	BUY	N/A	269	269 $1,000

Others Institutions Holding AXSM

# of Institutions

288

Shares Held

40.4M

Call Options Held

365K

Put Options Held

428K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.84B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account